GW sells priority review voucher for $105m
GW Pharmaceuticals is selling its rare paediatric disease priority review voucher (PRV) for $105 million to Biohaven Pharmaceutical.
Read More
Tag: PRV
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
